Advertisement

The critical role of histology in distinguishing sarcoidosis from common variable immunodeficiency disorder (CVID) in a patient with hypogammaglobulinemia

  • Rohan AmeratungaEmail author
  • Yeri Ahn
  • Dominic Tse
  • See-Tarn Woon
  • Jennifer Pereira
  • Sinead McCarthy
  • Hilary Blacklock
Open Access
Case report

Abstract

Background

Common variable immunodeficiency disorders (CVID) are a rare group of primary immune defects, where the underlying cause is unknown. Approximately 10–20% of patients with typical CVID have a granulomatous variant, which has closely overlapping features with sarcoidosis.

Case presentation

Here we describe a young man who sequentially developed refractory Evans syndrome, cauda equina syndrome and most recently renal impairment. Following immunosuppression, he has made a recovery from all three life-threatening autoimmune disorders. As the patient was hypogammaglobulinemic for most of the time while on immunosuppression, vaccine challenges and other tests were not possible. Histological features were in keeping with sarcoidosis rather than the granulomatous variant of CVID. In the brief period when immunosuppression was lifted between the cauda equina syndrome and renal impairment, he normalised his immunoglobulins, confirming sarcoidosis rather than CVID was the underlying cause.

Conclusion

We discuss diagnostic difficulties distinguishing the two conditions, and the value of histological features in our diagnostic criteria for CVID in identifying sarcoidosis, while the patient was hypogammaglobulinemic. The key message from this case report is that the characteristic histological features of CVID can be very helpful in making (or excluding) the diagnosis, particularly when other tests are not possible.

Keywords

CVID Sarcoidosis IVIG Neurosarcoidosis Diagnostic criteria 

Background

Common variable immunodeficiency disorders (CVID) are a rare group of primary immunodeficiency disorders (PIDs) leading to immune system failure (ISF) caused by late onset antibody failure (LOAF). The majority of CVID patients have profound hypogammaglobulinemia associated with antibody defects [1]. The genetic basis is unknown in the majority of patients with a CVID phenotype. If a causative mutation is identified, patients are removed from the umbrella diagnosis of CVID and are deemed to have a CVID-like disorder consequent to a specific PID [2].

Most patients with CVID and CVID-like disorders are predisposed to recurrent infections because of ISF. Approximately 10–15% of patients with typical CVID have clinical features which closely resembles sarcoidosis [3, 4, 5, 6]. This has been termed the granulomatous variant of CVID (GVCVID). Patients with GVCVID appear to have an increased risk of autoimmunity [7].

GVCVID and sarcoidosis can be very difficult to distinguish because of closely overlapping clinical features (Table 1) [7]. As with sarcoidosis, GVCVID typically involves the lung, liver and lymph nodes. A variety of thoracic radiological features can be seen including lymphadenopathy and interstitial lung disease [8, 9]. The pulmonary changes are collectively referred to as granulomatous interstitial lung disease (GLILD) [7, 10]. Histological correlates of GLILD include non-caseating granulomas, follicular bronchiolitis and lymphoid interstitial pneumonitis. In contrast to sarcoidosis, plasma cells are absent in GVCID and germinal centres are often poorly formed or disrupted.
Table 1

Differential diagnosis: comparison of the features of GVCVID with sarcoidosis

Parameter

GVCVID

Sarcoidosis

Comment

Clinical features

 Infections

More common

Uncommon

Favours sarcoidosis

 Lymphadenopathy

Common

Common

Does not differentiate

 Evans syndrome

Relatively common

Exceedingly rare

Only two cases described in sarcoid: strongly favours CVID

 Interstitial lung disease

Less common

Common

No obvious interstitial lung disease: favours CVID

 Steroid responsive renal disease

Very rare

Described in sarcoidosis

Strongly favours sarcoidosis

 Raised intracranial pressure

Rare

More common

Favours sarcoidosis

 MRI showing cauda equina involvement

No reports

Very rare

Cauda equina involvement described only in sarcoidosis

Laboratory features

 Switched memory B cells absent

Consistent with CVID

Reduced memory B cells

Favours CVID

 Angiotensin converting enzyme levels (ACE)

ACE levels can be elevated in GVCVID

ACE levels can be normal in sarcoidosis

Non discriminatory

 Absent TRECs

Favours LOCID but on MMF

Not described

Favours CVID

 CSF findings: only increased protein

 

Cells expected

Favours CVID

 Initial IgG normal but subsequent decrease, but normalised after stopping immunosuppression

Decreased

Increased

Strongly favours sarcoidosis and excludes CVID

 Lymph node: disrupted architecture

Disrupted architecture in CVID

Plasma cells and germinal centres present

Strongly favours sarcoidosis

Most clinical and laboratory abnormalities can occur in both disorders. Overall the findings strongly favour sarcoidosis. The normalisation of IgG and the histological findings subsequently excluded CVID. See text for abbreviations

There is no single clinical or laboratory feature which is pathognomonic for CVID. In areas of uncertainty diagnostic criteria can be very useful. The ESID/PAGID (1999) and ICON (2016) diagnostic criteria for CVID emphasise poor vaccine responses [11, 12]. Serological responses to vaccines can however be difficult to assess when patients are either being treated with subcutaneous or intravenous immunoglobulin (SCIG/IVIG) or when immunosuppressed for autoimmunity. These vaccine based CVID diagnostic criteria are thus difficult to apply in complex cases such as the patient described here. Furthermore, our recent prospective NZ Hypogammaglobulinemia study (NZHS) has shown the unreliability of vaccine responses in distinguishing patients with symptomatic and asymptomatic hypogammaglobulinemia, who have an excellent long-term prognosis [13]. The ESID/PAGID (1999) and ICON (2016) criteria do not include any of the characteristic histological features of CVID.

In 2013, we described new diagnostic criteria for CVID [14, 15]. These criteria include clinical, serological and histological features of the disorder, which allows a more precise diagnosis. CVID was previously a diagnosis of exclusion, but can now be made with greater precision. To fulfil our criteria, patients are required to have significant symptomatic hypogammaglobulinemia with no other explanation for the disorder. Supportive serological markers including poor or transient vaccine responses, absent isohemagglutinins, IgG3, IgA or IgM deficiency along with tests for significant autoimmunity. Importantly, our CVID diagnostic criteria also include histological features of the disorder including absence of plasma cells. Our reasoning was that histological features may be useful, when SCIG/IVIG treatment or immunosuppression preclude assessing serological tests. They can also be helpful in historical cases where the patient is deceased, if there are histological specimens from previous investigations. While these histological features can occur in other disorders, the primary symptomatic hypogammaglobulinemia confers specificity for CVID in our criteria.

Here we describe the value of histology in excluding CVID in a patient who was immunosuppressed for life-threatening autoimmunity and placed on IVIG for severe hypogammaglobulinemia. The histological features were strongly indicative of sarcoidosis rather than GVCVID. The patients IgG subsequently normalised when immunosuppression was briefly lifted, confirming that sarcoidosis rather than GVCVID was the underlying disorder. A normal IgG excludes CVID in all current diagnostic criteria.

Case presentation

The 22-year-old male patient presented at age 14 years with epistaxis related to severe thrombocytopenia. Immune thrombocytopenic purpura (ITP) was diagnosed and he was initially treated with high doses of prednisone. Prior to immunosuppression, his immunoglobulins had been measured and were found to be in the normal range (IgG 8.8 g/l, nr 7–14). Following initiation of steroid therapy he became hypogammaglobulinemic (IgG 4.3 g/l).

Once the severe hypogammaglobulinemia was identified, he was treated with IVIG (2 g/kg), with the added expectation the immunomodulatory doses of IVIG would reduce his risk of infections as well as potentially benefitting his ITP. He then developed Evans syndrome with autoimmune haemolytic anaemia, in addition to the ITP. When reviewed in 2011, he was Cushingoid from corticosteroids. He responded to this regimen and the prednisone was tapered to 10 mg daily and stopped.

He was well until 2013 when his ITP relapsed. On this occasion he did not respond to high dose prednisone, vincristine, cyclosporine, cyclophosphamide or rituximab. Due to ongoing cytopenias he underwent a splenectomy in 2014. Histology revealed the presence of splenic granulomas. Although the splenectomy was not successful, he remitted with eltrombopag in 2014.

He remained well until early 2017 when he developed diplopia consequent to bilateral cranial VI nerve palsies. He had headaches, fever and signs of meningism. Lumbar puncture showed an elevated CSF opening pressure but protein and other cellular parameters were normal. CSF bacterial culture, fungal antigen tests and viral PCR studies excluded infection. MRI of the brain showed an ill-defined enhancing area around the anterior pons.

He had widespread lymphadenopathy including mediastinal and abdominal lymphadenopathy on MRI scanning. Excision biopsy of a left inguinal lymph node showed the presence of discrete non-caseating granulomas, reactive follicles and overall normal lymph node architecture (Fig. 1a). Plasma cells were present although slightly reduced compared to a normal control (Fig. 1b, c). His serum angiotensin converting enzyme (ACE) level was normal.
Fig. 1

Lymph nodes from the patient (a, b) and normal control (c). Plasma cells staining with CD138 are shown in brown. a The patient has normal lymph node architecture. b Showing reduced numbers of plasma cells in the germinal centre in the patient. c The plasma cells are in the interfollicular areas in the control. CVID is typically associated with the absence of plasma cells and poorly formed germinal centres. The patient was not on immunosuppression at the time of the lymph node excision

The following week he developed increasing gait instability and was readmitted to hospital. Repeat CSF examination again showed an increased opening pressure (23 cm) and a raised protein level. The cell count and glucose were again normal. A repeat MRI scan of brain and spine revealed enhancing lesions in the cauda equina roots suggestive of granulomatous inflammation (Fig. 2). The previous pontine lesion had resolved. Given the location of inflammation, a biopsy was not possible. Nerve conduction tests of the lower limbs were consistent with nerve root involvement. Several months after starting steroids, a gallium PET scan showed enhancing lesions of the lacrimal gland.
Fig. 2

MRI of the cauda equina. Enhancing lesions of the nerve roots are seen consistent with granulomatous inflammation. A biopsy was not possible, given the location

PCR studies of the CSF and blood were negative for toxoplasma and tuberculosis (TB), the two main infectious differential diagnoses for granulomatous infections in New Zealand. He had not recently travelled internationally. He had a good response to IV methylprednisolone (1 g) treatment with resolution of headaches and fever, as well as improvement in gait. He was able walk unaided. The improvement was reflected in the blood tests, with the CRP decreasing from 69 to 7 mg/l within a week, and improving cytopenias. He was placed on low dose oral prednisone and mycophenolate with iv methylprednisolone 1 g every 2 weeks.

In mid-2018 when the immunosuppression was lifted, his IgG increased from 3.0 g/l to 8.8 g/l (Fig. 3) and the previously decreased IgA and IgM also normalised. Shortly afterwards he developed progressive renal impairment with a creatinine clearance of 36 ml/min. Renal biopsy showed 18/42 sclerosed glomeruli. No granulomas were identified. He was recommenced on Mycophenolate (MMF) and low dose prednisone. There was insufficient time to undertake vaccine response or detailed immunophenotyping studies before the immunosuppression was urgently recommenced. Over the following 6 months the creatinine clearance increased to 66 ml/min. The family has undergone whole exome sequencing for diagnosis and gene discovery but no causative mutation was identified [16].
Fig. 3

IgG levels during immunosuppression. In mid-2018 the IgG normalised briefly between resolution of the cauda equine syndrome and treatment of renal disease. Cauda Cauda equine syndrome, Evans Evans syndrome, ITP immune thrombocytopenia, IVIG intravenous immunoglobulin, IS immunosuppression, Renal renal impairment

Discussion and conclusion

This patient illustrates the difficulty in distinguishing sarcoidosis from the granulomatous variant of CVID because of the closely overlapping features (Table 1) [3]. Both are associated with organ dysfunction caused by multisystem granulomas [17]. There is a marked difference in long-term prognosis between the two conditions [18]. There are other important therapeutic implications in determining the exact underlying condition. Patients without an underlying immunodeficiency may be better able to tolerate immunosuppression. Some drugs such as TNF inhibitors may be more effective for neurosarcoidosis than GVCVID.

Approximately twenty-five percent of CVID patients have a causative mutation and if identified are classified as having a CVID-like disorder [19, 20]. All current CVID diagnostic criteria exclude patients with a known disorder, including causative mutations. This is the basis of separating CVID from CVID-like disorders. Identification of an underlying genetic defect also has profound implications for the family [19, 20, 21]. In contrast, no underlying causative genetic defect has been identified in sarcoidosis. We did not identify a causative mutation in this family. The absence of a mutation does not exclude either CVID or sarcoidosis.

Sarcoidosis and GVCVID are associated with lymphadenopathy and the lungs are involved in both disorders, although there may be subtle differences in the radiological findings between these two disorders [7]. Compared to GVCVID the majority of patients with sarcoidosis have interstitial lung disease [7]. The absence of interstitial lung disease in our patient favours GVCVID [8].

The neurological disease is more in keeping with sarcoidosis [22]. Raised intracranial pressure (ICP) has been described in neurosarcoidosis and may have been the explanation for the headaches and the bilateral VI cranial nerve palsies [23]. The raised ICP may have been either from previous prednisone treatment and/or meningeal involvement of the granulomas [24]. Although intracranial disease has been identified in GVCVID [25], cauda equina involvement has not. In one CVID patient with cauda equina syndrome, the authors felt their patient with CVID had concomitant neurosarcoidosis [26]. We therefore consider that our patient’s cauda equina syndrome to be more consistent with sarcoidosis.

Our patient had normal ACE levels. ACE levels can be elevated or normal in both GVCVID and sarcoidosis and are therefore non-discriminatory [27, 28]. Our patient had reduced memory B cells and absent switched memory B cells. We have shown variability in B cell numbers over time, repeat tests (4 years following last rituximab dose) but again showed absence of switched memory B cells [29]. Although reduction in switched memory B cells is also seen in sarcoidosis [30], complete absence would favour CVID. He was however on immunosuppression at the time.

Autoimmune cytopenias, are very rare in sarcoidosis [7]. ITP [31] and AIHA [32, 33, 34] have been individually been described in sarcoidosis but the combination leading to Evans syndrome appears to be exceptionally rare [35, 36]. In contrast, uveitis and autoimmune/inflammatory skin disease is more common in sarcoidosis [24]. The Evans syndrome in our patient therefore strongly favours CVID.

Although controversial, [37] vaccine challenge responses might be expected to be impaired in CVID compared with sarcoidosis but were not possible because the patient was already receiving intravenous immunoglobulin or immunosuppression for most of the last decade [38]. We have previously discussed the difficulties with the interpretation of vaccine responses in CVID [11]. We have recently shown the poor utility of vaccine responses in patients with primary hypogammaglobulinemia [13]. Even if we had been able to undertake vaccine challenge responses, they may not have excluded CVID.

The patient had absent T cell receptor excision circles (TRECS) suggestive of a severe T cell defect, although these were undertaken while on mycophenolate and oral prednisone. He has not suffered severe viral or opportunistic infections. There was no clinical suspicion of late onset combined immunodeficiency (LOCID), with viral and opportunistic infections [39]. Similarly, we did not undertake extended immunophenotyping because of the immunosuppression, given the potential difficulties interpreting the results.

Overall, the histological findings were strongly in favour of sarcoidosis (Table 1) [40]. Careful review of his lymph node histology and immunohistochemistry studies showed the presence of CD138 + staining plasma cells (Fig. 1b) and intact germinal centres. Although plasma cells were reduced compared to the control (Fig. 1c), their presence is diagnostic of sarcoidosis, in the absence of other granulomatous disorders.

His initial IgG was in the normal range but rapidly decreased following immunosuppression. Typically patients with sarcoidosis have elevated IgG levels, while CVID patients have levels < 5 g/l [15]. Immunosuppressive therapy such as rituximab can unmask CVID [41]. His IgG increased into the normal range when his immunosuppression was decreased, excluding CVID [42].

Prior to recovery of his IgG, he had many of the features of the revised ESID registry (2014) criteria for CVID as he had a granulomatous disorder, reduction in IgG and IgA, absent switched memory B cells with an age of onset greater than 4 years. He did not however meet the revised ESID registry (2014) criteria because of the immunosuppression, where a secondary cause could not be excluded [43]. Absence of plasma cells are not part of the revised ESID registry (2014) criteria, which is probably the most important clue to this clinical conundrum, in allowing the correct diagnosis.

We have previously shown that histological features of our diagnostic criteria were similarly helpful in another patient who had both CVID and drug induced hypogammaglobulinemia (Category D in the Ameratunga et al. criteria) [44]. This case report highlights the value of histology in being able to make a firm diagnosis, where other tests were not possible or inconclusive. Given the difficulties interpreting vaccine challenge responses in patients with hypogammaglobulinemia, histology is likely to much more useful in the diagnosis of similar patients.

Notes

Acknowledgements

We acknowledge the support of ADHB for our research studies.

Authors’ contributions

RA, JP, DT HB were clinically responsible for this patient. YA, S-TW and SMc contributed to the editing of the manuscript. RA wrote the first draft. All authors read and approved the final manuscript.

Funding

This study was not externally funded.

Ethics approval and consent to participate

The patient has given consent to participate in our studies including publication of findings for the benefit of others. This study is approved by Health and Disability Ethics Committee (HDEC) of the NZ Ministry of Health and the ADHB ethics committee.

Consent for publication

The patient has consented to publication as part of the NZ hypogammaglobulinemia study.

Competing interests

The authors declare that they have no competing interests.

References

  1. 1.
    Abbott JK, Gelfand EW. Common variable immunodeficiency: diagnosis, management, and treatment. Immunol Allergy Clin N Am. 2015;35:637–58.CrossRefGoogle Scholar
  2. 2.
    Ameratunga R, Lehnert K, Woon ST, et al. Review: Diagnosing common variable immunodeficiency disorder in the era of genome sequencing. Clin Rev Allergy Immunol. 2018;54:261–8.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Ameratunga R, Becroft DM, Hunter W. The simultaneous presentation of sarcoidosis and common variable immune deficiency. Pathology. 2000;32:280–2.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Arnold DF, Wiggins J, Cunningham-Rundles C, Misbah SA, Chapel HM. Granulomatous disease: distinguishing primary antibody disease from sarcoidosis. Clin Immunol. 2008;128:18–22.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Ardeniz O, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Clin Immunol. 2009;133:198–207.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Fasano MB, Sullivan KE, Sarpong SB, et al. Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature. Medicine. 1996;75:251–61.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Verbsky JW, Routes JM. Sarcoidosis and common variable immunodeficiency: similarities and differences. Semin Respir Crit Care Med. 2014;35:330–5.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    de Boer S, Wilsher M. Review series: Aspects of interstitial lung disease. Sarcoidosis. Chron Respir Dis. 2010;7:247–58.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Jolles S, Carne E, Brouns M, et al. FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clin Exp Immunol. 2017;187:138–45.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Prasse A, Kayser G, Warnatz K. Common variable immunodeficiency-associated granulomatous and interstitial lung disease. Curr Opin Pulm Med. 2013;19:503–9.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Ameratunga R, Brewerton M, Slade C, et al. Comparison of diagnostic criteria for common variable immunodeficiency disorder. Front Immunol. 2014;5:415.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Ameratunga R, Gillis D, Steele R. Diagnostic criteria for common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4:1017–8.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Ameratunga R, Ahn Y, Steele R, Woon S-T. The natural history of untreated primary hypogammaglobulinemia in adults: implications for the diagnosis and treatment of common variable immunodeficiency disorders (CVID). Front Immunol. 2019;17(10):1541.CrossRefGoogle Scholar
  14. 14.
    Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol. 2013;174:203–11.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for CVID. Expert Rev Clin Immunol. 2014;10:183–6.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Ameratunga R. Initial intravenous immunoglobulin doses should be based on adjusted body weight in obese patients with primary immunodeficiency disorders. Allergy Asthma Clin Immunol. 2017;13:47.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Shanks AM, Alluri R, Herriot R, Dempsey O. Misdiagnosis of common variable immune deficiency. BMJ Case Rep. 2014;2014:bcr2013202806.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Bouvry D, Mouthon L, Brillet PY, et al. Granulomatosis-associated common variable immunodeficiency disorder: a case-control study versus sarcoidosis. Eur Respir J. 2013;41:115–22.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Ameratunga R, Woon ST, Brewerton M, et al. Primary immune deficiency disorders in the South Pacific: the clinical utility of a customized genetic testing program in New Zealand. Ann N Y Acad Sci. 2011;1238:53–64.PubMedCrossRefGoogle Scholar
  20. 20.
    Ameratunga R, Woon ST, Neas K, Love DR. The clinical utility of molecular diagnostic testing for primary immune deficiency disorders: a case based review. Allergy Asthma Clin Immunol. 2010;6:12.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Ameratunga R, Woon ST. Customised molecular diagnosis of primary immune deficiency disorders in New Zealand: an efficient strategy for a small developed country. N Z Med J. 2009;122:46–53.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Nguyen JT, Green A, Wilson MR, DeRisi JL, Gundling K. Neurologic complications of common variable immunodeficiency. J Clin Immunol. 2016;36:793–800.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Ibitoye RT, Wilkins A, Scolding NJ. Neurosarcoidosis: a clinical approach to diagnosis and management. J Neurol. 2017;264(5):1023–8.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Rao DA, Dellaripa PF. Extrapulmonary manifestations of sarcoidosis. Rheum Dis Clin North Am. 2013;39:277–97.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Najem CE, Springer J, Prayson R, et al. Intra cranial granulomatous disease in common variable immunodeficiency: case series and review of the literature. Semin Arthritis Rheum. 2018;47:890–6.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Dziadzio M, Hortobagyi T, Kidd D, Chee R. Common variable immunodeficiency with coexisting central nervous system sarcoidosis: case report and literature review with implications for diagnosis and pathogenesis. Ideggyogy Sz. 2011;64:405–8.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Mrusek S, Marx A, Kummerle-Deschner J, et al. Development of granulomatous common variable immunodeficiency subsequent to infection with Toxoplasma gondii. Clin Exp Immunol. 2004;137:578–83.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Baba Y, Kubo T, Yamanaka S, et al. Reconsideration of the cut-off value of angiotensin-converting enzyme for screening of sarcoidosis in Japanese patients. J Cardiol. 2019;74:507–11.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Koopmans W, Woon ST, Zeng IS, et al. Variability of memory B cell markers in a cohort of common variable immune deficiency patients over six months. Scand J Immunol. 2013;77:470–5.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Lee NS, Barber L, Akula SM, Sigounas G, Kataria YP, Arce S. Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis. Clin Vaccine Immunol. 2011;18:1306–16.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Mahevas M, Chiche L, Uzunhan Y, et al. Association of sarcoidosis and immune thrombocytopenia: presentation and outcome in a series of 20 patients. Medicine. 2011;90:269–78.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Green S, Partridge E, Idedevbo E, Borg A. Steroid refractory autoimmune haemolytic anaemia secondary to sarcoidosis successfully treated with rituximab and mycophenolate mofetil. Case Rep Hematol. 2016;2016:9495761.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Ghaddar RK, Muzaffar TH. Pulmonary sarcoidosis and autoimmune hemolytic anemia: possible common immune pathogenesis. Arch Iran Med. 2011;14:146–8.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Desablens B, Pruna A, Gontier MF, Messerschmitt J. Autoimmune haemolytic anaemia associated with bone marrow sarcoidosis. Acta Haematol. 1984;71:204–6.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Kondo H, Sakai S, Sakai Y. Autoimmune haemolytic anaemia, Sjogren’s syndrome and idiopathic thrombocytopenic purpura in a patient with sarcoidosis. Acta Haematol. 1993;89:209–12.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Semple P. Thrombocytopenia, haemolytic anaemia, and sarcoidosis. Br Med J. 1975;4:440–1.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Beck SC. Making sense of serotype-specific pneumococcal antibody measurements. Ann Clin Biochem. 2013;50:517–9.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Empson M, Sinclair J, O’Donnell J, Ameratunga R, Fitzharris P, Steele R. The assessment and management of primary antibody deficiency. N Z Med J. 2004;117:U914.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Ameratunga RV. Resolution of extensive vulvovaginal condylomatosis following immunoglobulin replacement in primary immunodeficiency disorders. J Allergy Clin Immunol Prac. 2018;6:1053–5.CrossRefGoogle Scholar
  40. 40.
    Unger S, Seidl M, Schmitt-Graeff A, et al. Ill-defined germinal centers and severely reduced plasma cells are histological hallmarks of lymphadenopathy in patients with common variable immunodeficiency. J Clin Immunol. 2014;34:615–26.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Mogensen TH, Bernth-Jensen JM, Petersen CC, et al. Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with rituximab. BMC Hematol. 2013;13:4.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Duraisingham SS, Buckland MS, Grigoriadou S, Longhurst HJ. Secondary antibody deficiency. Expert Rev Clin Immunol. 2014;10:583–91.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Seidel MG, Kindle G, Gathmann B, et al. The European Society for Immunodeficiencies (ESID) Registry working definitions for the clinical diagnosis of inborn errors of immunity. J Allergy Clin Immunol Pract. 2019;7(6):1763–70.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Ameratunga R, Lindsay K, Woon S-T, Jordan A, Anderson NE, Koopmans W. New diagnostic criteria could distinguish common variable immunodeficiency disorder from anticonvulsant-induced hypogammaglobulinemia. Clin Exp Neuroimmunol. 2015;6:83–8.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Rohan Ameratunga
    • 1
    • 4
    Email author
  • Yeri Ahn
    • 1
  • Dominic Tse
    • 2
  • See-Tarn Woon
    • 1
    • 4
  • Jennifer Pereira
    • 2
  • Sinead McCarthy
    • 3
  • Hilary Blacklock
    • 4
    • 5
  1. 1.Department of Virology and ImmunologyAuckland City HospitalAucklandNew Zealand
  2. 2.Department of NeurologyAuckland City HospitalAucklandNew Zealand
  3. 3.Department of HistopathologyAuckland City HospitalAucklandNew Zealand
  4. 4.Department of Molecular Medicine and Pathology, Faculty of Medical and Health SciencesUniversity of AucklandAucklandNew Zealand
  5. 5.Department of HaematologyMiddlemore HospitalAucklandNew Zealand

Personalised recommendations